Newsletter Subscribe
Sign up now to stay up to date with the latest news and developments.
Thank you
Please check your inbox to confirm your subscription.
ARC Portal contributes to the broader effort to improve understanding, strengthen evidence, and support better care for people living with rare cancers by partnering with the WEHI Stafford Fox Rare Cancer Program.
The WEHI Stafford Fox Rare Cancer Program is a research initiative dedicated to improving understanding and treatment of rare cancers.
Based at the Walter and Eliza Hall Institute of Medical Research (WEHI), the program collects de-identified clinical information to support rare cancer research. Once there is sufficient data for a particular type of cancer, it can be analysed to improve our understanding of that cancer.
By bringing together information from across Australia, researchers can better understand rare cancers, identify trends, and generate evidence that may improve future patient care.
Patients referred through ARC Portal provide consent for their information to contribute to this research. Participation is voluntary and governed by strict ethical and privacy requirements.
The WEHI Stafford Fox Rare Cancer Program has been approved by the Melbourne Health Human Research and Ethics Committee (HREC/15/MH/396).
Rare cancers present unique challenges for clinicians, researchers, and patients alike.
Compared with more common cancers, there may be:
Research helps address these challenges by improving understanding of rare cancers, identifying new treatment opportunities, and building the evidence needed to support future clinical decision-making.
Every rare cancer case has the potential to contribute to a better understanding of rare cancers.
Through collaboration between clinicians, researchers, and specialist networks, knowledge gained from individual cases can help identify patterns, uncover evidence gaps, and generate new research questions.
Over time, these insights contribute to a stronger evidence base that can improve diagnosis, treatment planning, and access to care for future patients.
The ultimate goal of rare cancer research is better patient outcomes.
ARC Portal contributes to publications, conference presentations, and other research outputs that help advance understanding of rare cancers and share learnings across the healthcare community.
If you would like to learn more about ARC Portal's contribution to rare cancer research, research partnerships, or ongoing initiatives, we welcome your enquiry.